MoonLake's Quarterly Loss Widens To $79.5 Million As It Files Its First FDA Application
The biotech says $498.5 million in cash lasts to mid-2028, and up to $400 million more is available through a Hercules Capital debt facility.
MoonLake Immunotherapeutics, a clinical-stage biotech developing treatments for inflammatory skin and joint diseases, posted a third-quarter net loss of $79.5 million, or $0.93 per share, in results released Wednesday. That compares with a $61.8 million loss, or $0.84 per share, in the second quarter, as the company submitted its first FDA approval application for sonelokimab in hidradenitis suppurativa.
Milestone fees drive the bigger loss
Research and development spending rose to $68.9 million from $50.2 million in the second quarter. The $18.7 million increase came mainly from accrued milestone license fees tied to a regulatory milestone, linked to the expected acceptance of the application.
General and administrative expenses were $11.0 million, against $11.4 million in the prior quarter. Weighted-average shares rose to 85.4 million from 73.9 million.
Cash to mid-2028
MoonLake held $498.5 million in cash, cash equivalents and short-term marketable debt securities on September 30, and expects that to fund operations to mid-2028. A debt facility with Hercules Capital provides up to $400 million more in non-dilutive funds, meaning money that does not issue new shares.
Chief Financial Officer Matthias Bodenstedt said the runway positions the company well to prepare for "the expected commercial launch of sonelokimab in the U.S. next year." The company expects that launch in the second half of 2027.
One drug, several trials
MoonLake has a single product candidate, sonelokimab, a Nanobody (a small antibody-like protein) that blocks the inflammation-driving proteins IL-17A and IL-17F. It has no products on the market and is also testing the drug in psoriatic arthritis, palmoplantar pustulosis and axial spondyloarthritis.
The application, submitted September 30, covers adults and adolescents 12 and older with moderate-to-severe hidradenitis suppurativa. In psoriatic arthritis, the Phase 3 IZAR-1 trial met all clinical endpoints at Week 16 for the 60 mg dose, with 42.1% of biologic-naïve patients reaching an ACR50 response, a measure of at least 50% improvement in symptoms. Enrollment in the companion IZAR-2 trial finished in September.
FDA decisions due by mid-December
MoonLake expects to learn by the end of November whether the FDA accepts the application for review. A decision on Priority Review and the review timeline is expected by mid-December.
IZAR-2 Week 16 results are due in the first quarter of 2027, and enrollment in the Phase 3 NOVA trial in palmoplantar pustulosis is planned to start in November.
The next test comes by the end of November, when the FDA is expected to say whether it will accept the sonelokimab application for review.
Sources
- 8-K Filing — MoonLake Immunotherapeutics (MLTX) — SEC EDGAR
- Exhibit moonlake-pressreleasexq320.htm — MoonLake Immunotherapeutics 8-K exhibit — SEC EDGAR